Pharma

Meiji Seika Pharma Supports Lyric Bio in Ig Manufacturing

Meiji Seika Pharma Co., Ltd. announced a strategic equity investment in Lyric Bio, Inc. Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio’s ongoing R&D activities and implementation of its IVIg manufacturing platform, strengthening the cooperative relationship between Meiji Seika Pharma and Lyric Bio.…